{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:46:18Z","timestamp":1782384378820,"version":"3.54.5"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UH3DA050311"],"award-info":[{"award-number":["UH3DA050311"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA055825"],"award-info":[{"award-number":["R01DA055825"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA058958"],"award-info":[{"award-number":["R01DA058958"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40263-026-01300-0","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:24:13Z","timestamp":1779171853000},"page":"883-899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Opioid Use Disorder Treatment Gaps and Emerging Therapeutics to Address Them"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4949-5246","authenticated-orcid":false,"given":"Matthew L.","family":"Banks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"1300_CR1","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators int he United States: results from the 2024 National Survey on Drug Use and Health (HHS Publication No. PEP25-07-007, NSDUH Series H-60). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Rockville: Substance Abuse and Mental Health Services Administration; 2025. p. 1\u2013132. https:\/\/www.samhsa.gov\/data\/data-we-collect\/nsduh-national-survey-drug-use-and-health\/national-releases."},{"issue":"10513","key":"1300_CR2","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(25)01917-8","volume":"406","author":"M Naghavi","year":"2025","unstructured":"Naghavi M, Kyu HH, Bhoomadevi A, Aalipour MA, Aalruz H, Ababneh HS, et al. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990\u20132023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10513):1811\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(25)01917-8.","journal-title":"Lancet"},{"issue":"5","key":"1300_CR3","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1016\/S2214-109X(23)00058-X","volume":"11","author":"S Colledge-Frisby","year":"2023","unstructured":"Colledge-Frisby S, Ottaviano S, Webb P, Grebely J, Wheeler A, Cunningham EB, et al. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. Lancet Glob Health. 2023;11(5):e673\u201383. https:\/\/doi.org\/10.1016\/S2214-109X(23)00058-X.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"1300_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/wps.20633","volume":"18","author":"ND Volkow","year":"2019","unstructured":"Volkow ND, Icaza MEM-M, Poznyak V, Saxena S, Gerra G, Network tU-WIS. Addressing the opioid crisis globally. World Psychiatry. 2019;18(2):231\u20132. https:\/\/doi.org\/10.1002\/wps.20633.","journal-title":"World Psychiatry"},{"issue":"1","key":"1300_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0137-5","volume":"6","author":"J Strang","year":"2020","unstructured":"Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, et al. Opioid use disorder. Nat Rev Dis Primers. 2020;6(1):3. https:\/\/doi.org\/10.1038\/s41572-019-0137-5.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1300_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S0022-3565(24)37462-2","volume":"285","author":"DE Selley","year":"1998","unstructured":"Selley DE, Liu Q, Childers SR. Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP\u03b3S binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther. 1998;285(2):496\u2013505. https:\/\/doi.org\/10.1016\/S0022-3565(24)37462-2.","journal-title":"J Pharmacol Exp Ther"},{"key":"1300_CR7","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.32499","volume":"7","author":"KE Livingston","year":"2018","unstructured":"Livingston KE, Mahoney JP, Manglik A, Sunahara RK, Traynor JR. Measuring ligand efficacy at the mu-opioid receptor using a conformational biosensor. Elife. 2018;7:e32499. https:\/\/doi.org\/10.7554\/eLife.32499.","journal-title":"Elife"},{"key":"1300_CR8","volume-title":"The selection and use of essential medicines: report of the WHO Expert Committee","author":"WHO Expert Committee on the Selective and Use of Essential Medicines","year":"2005","unstructured":"WHO Expert Committee on the Selective and Use of Essential Medicines. The selection and use of essential medicines: report of the WHO Expert Committee. 14th ed. Geneva: WHO; 2005.","edition":"14"},{"issue":"7410","key":"1300_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7410.310","volume":"327","author":"W van den Brink","year":"2003","unstructured":"van den Brink W, Hendriks VM, Blanken P, Koeter MWJ, van Zwieten BJ, van Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 2003;327(7410):310. https:\/\/doi.org\/10.1136\/bmj.327.7410.310.","journal-title":"BMJ"},{"issue":"8","key":"1300_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.10156\/NEJM0810635","volume":"361","author":"E Oviedo-Joekes","year":"2009","unstructured":"Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777\u201386. https:\/\/doi.org\/10.10156\/NEJM0810635.","journal-title":"N Engl J Med"},{"issue":"1","key":"1300_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02406-5","volume":"13","author":"MS Milella","year":"2023","unstructured":"Milella MS, D\u2019Ottavio G, De Pirro S, Barra M, Caprioli D, Badiani A. Heroin and its metabolites: relevance to heroin use disorder. Transl Psychiatry. 2023;13(1):120. https:\/\/doi.org\/10.1038\/s41398-023-02406-5.","journal-title":"Transl Psychiatry"},{"key":"1300_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007522.pub2","author":"A Rahimi-Movaghar","year":"2018","unstructured":"Rahimi-Movaghar A, Gholami J, Amato L, Hoseinie L, Yousefi-Nooraie R, Amin-Esmaeili M. Pharmacological therapies for management of opium withdrawal. Cochrane Database Syst Rev. 2018. https:\/\/doi.org\/10.1002\/14651858.CD007522.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1300_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.japh.2019.10.004","volume":"60","author":"AK Kuszmaul","year":"2020","unstructured":"Kuszmaul AK, Palmer EC, Frederick EK. Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: a systematic review. J Am Pharm Assoc. 2020;60(1):145\u201352. https:\/\/doi.org\/10.1016\/j.japh.2019.10.004.","journal-title":"J Am Pharm Assoc"},{"issue":"1","key":"1300_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","volume":"87","author":"J Bell","year":"2020","unstructured":"Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020;87(1):82\u20138. https:\/\/doi.org\/10.1016\/j.biopsych.2019.06.020.","journal-title":"Biol Psychiatry"},{"key":"1300_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013672.pub2","author":"D Perry","year":"2025","unstructured":"Perry D, Kirkwood JEM, Doroshuk ML, Kelmer M, Korownyk CS, Ton J, et al. Opioid agonist therapy for opioid use disorder in primary versus specialty care. Cochrane Database Syst Rev. 2025. https:\/\/doi.org\/10.1002\/14651858.CD013672.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1300_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1141093","author":"W Bremer","year":"2023","unstructured":"Bremer W, Plaisance K, Walker D, Bonn M, Love JS, Perrone J, et al. Barriers to opioid use disorder treatment: a comparison of self-reported information from social media with barriers found in literature. Front Public Health. 2023. https:\/\/doi.org\/10.3389\/fpubh.2023.1141093.","journal-title":"Front Public Health"},{"key":"1300_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011117.pub3","author":"S Nielsen","year":"2022","unstructured":"Nielsen S, Tse WC, Larance B. Opioid agonist treatment for people who are dependent on pharmaceutical opioids. Cochrane Database Syst Rev. 2022. https:\/\/doi.org\/10.1002\/14651858.CD011117.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1300_CR18","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41386-019-0336-5","volume":"44","author":"ML Banks","year":"2019","unstructured":"Banks ML, Townsend EA, Negus SS. Testing the 10 most wanted: a preclinical algorithm to screen candidate opioid use disorder medications. Neuropsychopharmacology. 2019;44:1011\u20132. https:\/\/doi.org\/10.1038\/s41386-019-0336-5.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"1300_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41386-018-0292-5","volume":"44","author":"K Rasmussen","year":"2019","unstructured":"Rasmussen K, White DA, Acri JB. NIDA\u2019s medication development priorities in response to the opioid crisis: ten most wanted. Neuropsychopharmacology. 2019;44(4):657\u20139. https:\/\/doi.org\/10.1038\/s41386-018-0292-5.","journal-title":"Neuropsychopharmacology"},{"key":"1300_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41583-020-0378-z","volume":"21","author":"M Venniro","year":"2020","unstructured":"Venniro M, Banks ML, Heilig M, Epstein DH, Shaham Y. Improving translation of animal models of addiction and relapse by reverse translation. Nat Rev Neurosci. 2020;21:625\u201343. https:\/\/doi.org\/10.1038\/s41583-020-0378-z.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"1300_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a039263","volume":"11","author":"EA Townsend","year":"2021","unstructured":"Townsend EA, Negus SS, Banks ML. Medications development for treatment of opioid use disorder. Cold Spring Harb Perspect Med. 2021;11(1):a039263. https:\/\/doi.org\/10.1101\/cshperspect.a039263.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1300_CR22","first-page":"1","volume-title":"Morphine addiction in Chimpanzees. Comparative psychology monographs","author":"SDS Spragg","year":"1940","unstructured":"Spragg SDS. Morphine addiction in Chimpanzees. Comparative psychology monographs. Baltimore: The John Hopkins Press; 1940. p. 1\u2013132."},{"issue":"3","key":"1300_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0031-6997(25)06689-X","volume":"27","author":"RR Griffiths","year":"1975","unstructured":"Griffiths RR, Wurster RM, Brady JV. Discrete-trial choice procedure: effects of naloxone and methadone on choice between food and heroin. Pharmacol Rev. 1975;27(3):357\u201365.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"1300_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1124\/jpet.105.095380","volume":"317","author":"SS Negus","year":"2006","unstructured":"Negus SS. Choice between heroin and food in nondependent and heroin-dependent Rhesus monkeys: effects of naloxone, buprenorphine, and methadone. J Pharmacol Exp Ther. 2006;317(2):711\u201323. https:\/\/doi.org\/10.1124\/jpet.105.095380.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"1300_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0893-133X(95)00274-H","volume":"14","author":"NK Mello","year":"1996","unstructured":"Mello NK, Negus SS. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology. 1996;14(6):375\u2013424. https:\/\/doi.org\/10.1016\/0893-133X(95)00274-H.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1300_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00213-008-1079-x","volume":"199","author":"M Haney","year":"2008","unstructured":"Haney M, Spealman R. Controversies in translational research: drug self-administration. Psychopharmacology. 2008;199(3):403\u201319. https:\/\/doi.org\/10.1007\/s00213-008-1079-x.","journal-title":"Psychopharmacology"},{"key":"1300_CR27","doi-asserted-by":"publisher","DOI":"10.2307\/j.ctvjf9xd9","volume-title":"Addiction: a disorder of choice","author":"GH Heyman","year":"2009","unstructured":"Heyman GH. Addiction: a disorder of choice. Cambridge: Harvard University Press; 2009."},{"issue":"2","key":"1300_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.neubiorev.2010.04.00529","volume":"35","author":"SH Ahmed","year":"2010","unstructured":"Ahmed SH. Validation crisis in animal models of drug addiction: beyond non-disordered drug use toward drug addiction. Neurosci Biobehav Rev. 2010;35(2):172\u201384. https:\/\/doi.org\/10.1016\/j.neubiorev.2010.04.00529.","journal-title":"Neurosci Biobehav Rev"},{"key":"1300_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/281768","volume":"2012","author":"ML Banks","year":"2012","unstructured":"Banks ML, Negus SS. Preclinical determinants of drug choice under concurrent schedules of drug self-administration. Adv Pharmacol Sci. 2012;2012:281768. https:\/\/doi.org\/10.1155\/2012\/281768.","journal-title":"Adv Pharmacol Sci"},{"issue":"5","key":"1300_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s44159-023-00167-y","volume":"2","author":"SF Acuff","year":"2023","unstructured":"Acuff SF, MacKillop J, Murphy JG. A contextualized reinforcer pathology approach to addiction. Nat Rev Psychol. 2023;2(5):309\u201323. https:\/\/doi.org\/10.1038\/s44159-023-00167-y.","journal-title":"Nat Rev Psychol"},{"issue":"12","key":"1300_CR31","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1111\/j.1360-0443.2007.02014.x","volume":"102","author":"FJ Vocci","year":"2007","unstructured":"Vocci FJ. Can replacement therapy work in the treatment of cocaine dependence? And what are we replacing anyway? Addiction. 2007;102(12):1888\u20139. https:\/\/doi.org\/10.1111\/j.1360-0443.2007.02014.x.","journal-title":"Addiction"},{"key":"1300_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pbb.2017.05.002","volume":"164","author":"RJ Lamb","year":"2017","unstructured":"Lamb RJ, Ginsburg BC. Addiction as a BAD, a behavioral allocation disorder. Pharmacol Biochem Behav. 2017;164:62\u201370. https:\/\/doi.org\/10.1016\/j.pbb.2017.05.002.","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"1300_CR33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1124\/pr.115.011668","volume":"68","author":"PW Czoty","year":"2016","unstructured":"Czoty PW, Stoops WW, Rush CR. Evaluation of the \u201cpipeline\u201d for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research. Pharmacol Rev. 2016;68(3):533\u201362. https:\/\/doi.org\/10.1124\/pr.115.011668.","journal-title":"Pharmacol Rev"},{"key":"1300_CR34","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1300_CR35","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/s41386-019-0385-9","volume":"44","author":"EA Townsend","year":"2019","unstructured":"Townsend EA, Blake S, Faunce KE, Hwang CS, Natori Y, Zhou B, et al. Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats. Neuropsychopharmacology. 2019;44:1681\u20139. https:\/\/doi.org\/10.1038\/s41386-019-0385-9.","journal-title":"Neuropsychopharmacology"},{"key":"1300_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2021.109110","author":"EA Townsend","year":"2021","unstructured":"Townsend EA, Schwienteck KL, Robinson HL, Lawson ST, Banks ML. A drug-vs-food \u201cchoice\u201d self-administration procedure in rats to investigate pharmacological and environmental mechanisms of substance use disorders. J Neurosci Methods. 2021. https:\/\/doi.org\/10.1016\/j.jneumeth.2021.109110.","journal-title":"J Neurosci Methods"},{"key":"1300_CR37","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41386-022-01393-3","volume":"47","author":"EA Townsend","year":"2022","unstructured":"Townsend EA, Blough BE, Epstein DH, Negus SS, Shaham Y, Banks ML. Effect of TRV130 and methadone on fentanyl-vs.-food choice and somatic withdrawal signs in opioid-dependent and post-opioid-dependent rats. Neuropsychopharmacology. 2022;47:2132\u20139. https:\/\/doi.org\/10.1038\/s41386-022-01393-3.","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"1300_CR38","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/j.1360-0443.2005.01232.x","volume":"100","author":"EC Donny","year":"2005","unstructured":"Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. Methadone doses of 100\u2003mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction. 2005;100(10):1496\u2013509. https:\/\/doi.org\/10.1111\/j.1360-0443.2005.01232.x.","journal-title":"Addiction"},{"key":"1300_CR39","unstructured":"Negus SS. Opioid antagonist effects in animal models related to opioid abuse: drug discrimination and drug self-administration. Opiate receptors and antagonists: from bench to clinic. Springer; 2009. p. 201\u201326."},{"issue":"12","key":"1300_CR40","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41583-025-00982-7","volume":"26","author":"VP Mathis","year":"2025","unstructured":"Mathis VP, Ehrlich AT, Darcq E. The neural circuits and signalling pathways of opioid use disorder. Nat Rev Neurosci. 2025;26(12):778\u201397. https:\/\/doi.org\/10.1038\/s41583-025-00982-7.","journal-title":"Nat Rev Neurosci"},{"issue":"11","key":"1300_CR41","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrn3104","volume":"12","author":"A Badiani","year":"2011","unstructured":"Badiani A, Belin D, Epstein D, Calu D, Shaham Y. Opiate versus psychostimulant addiction: the differences do matter. Nat Rev Neurosci. 2011;12(11):685\u2013700. https:\/\/doi.org\/10.1038\/nrn3104.","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"1300_CR42","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1124\/pr.117.013904","volume":"69","author":"PT Bremer","year":"2017","unstructured":"Bremer PT, Janda KD. Conjugate vaccine immunotherapy for substance use disorder. Pharmacol Rev. 2017;69(3):298\u2013315. https:\/\/doi.org\/10.1124\/pr.117.013904.","journal-title":"Pharmacol Rev"},{"issue":"11","key":"1300_CR43","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.tips.2018.08.001","volume":"39","author":"ML Banks","year":"2018","unstructured":"Banks ML, Olson ME, Janda KD. Immunopharmacotherapies for treating opioid use disorder. Trends Pharmacol Sci. 2018;39(11):908\u201311. https:\/\/doi.org\/10.1016\/j.tips.2018.08.001.","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"1300_CR44","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1124\/jpet.120.000124","volume":"375","author":"C Baehr","year":"2020","unstructured":"Baehr C, Kelcher AH, Khaimraj A, Reed DE, Pandit SG, AuCoin D, et al. Monoclonal antibodies counteract opioid-induced behavioral and toxic effects in mice and rats. J Pharmacol Exp Ther. 2020;375(3):469\u201377. https:\/\/doi.org\/10.1124\/jpet.120.000124.","journal-title":"J Pharmacol Exp Ther"},{"key":"1300_CR45","doi-asserted-by":"publisher","first-page":"10489","DOI":"10.1021\/jacs.9b04872","volume":"141","author":"LC Smith","year":"2019","unstructured":"Smith LC, Bremer PT, Hwang CS, Zhou B, Ellis B, Hixon MS, et al. Monoclonal antibodies for combating synthetic opioid intoxication. J Am Chem Soc. 2019;141:10489\u2013503. https:\/\/doi.org\/10.1021\/jacs.9b04872.","journal-title":"J Am Chem Soc"},{"issue":"3","key":"1300_CR46","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13543784.2023.2187286","volume":"32","author":"S Martinez","year":"2023","unstructured":"Martinez S, Harris H, Chao T, Luba R, Pravetoni M, Comer SD, et al. The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis. Expert Opin Investig Drugs. 2023;32(3):181\u20135. https:\/\/doi.org\/10.1080\/13543784.2023.2187286.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5485","key":"1300_CR47","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/252708a0","volume":"252","author":"KF Bonese","year":"1974","unstructured":"Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature. 1974;252(5485):708\u201310. https:\/\/doi.org\/10.1038\/252708a0.","journal-title":"Nature"},{"issue":"9","key":"1300_CR48","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S2215-0366(22)00241-3","volume":"9","author":"RM Krausz","year":"2022","unstructured":"Krausz RM, Westenberg JN, Meyer M, Choi F. The upcoming synthetic ultrapotent opioid wave as a foreseeable disaster. Lancet Psychiatry. 2022;9(9):699\u2013700. https:\/\/doi.org\/10.1016\/S2215-0366(22)00241-3.","journal-title":"Lancet Psychiatry"},{"key":"1300_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108348","volume":"218","author":"EA Townsend","year":"2021","unstructured":"Townsend EA, Bremer PT, Jacob NT, Negus SS, Janda KD, Banks ML. A synthetic opioid vaccine attenuates fentanyl-vs-food choice in male and female rhesus monkeys. Drug Alcohol Depend. 2021;218:108348. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108348.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"1300_CR50","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00213-025-06751-9","volume":"242","author":"LK Galbo-Thomma","year":"2025","unstructured":"Galbo-Thomma LK, Marecki C, Kim CM, Hiranita T, Taylor JR, Maguire DR, et al. A humanized monoclonal antibody attenuates fentanyl self-administration and reverses and prevents fentanyl-induced ventilatory depression in rhesus monkeys. Psychopharmacology. 2025;242(8):1713\u201326. https:\/\/doi.org\/10.1007\/s00213-025-06751-9.","journal-title":"Psychopharmacology"},{"key":"1300_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2025.100365","volume":"16","author":"LK Galbo-Thomma","year":"2025","unstructured":"Galbo-Thomma LK, Baehr C, Gay EA, Runyon S, Pravetoni M, France CP. A humanized monoclonal antibody attenuates carfentanil self-administration in nonhuman primates. Drug Alcohol Depend Rep. 2025;16:100365. https:\/\/doi.org\/10.1016\/j.dadr.2025.100365.","journal-title":"Drug Alcohol Depend Rep."},{"key":"1300_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","volume":"144","author":"MK Greenwald","year":"2014","unstructured":"Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend. 2014;144:1\u201311. https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.07.035.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"1300_CR53","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0022-3565(25)38246-7","volume":"265","author":"SS Negus","year":"1993","unstructured":"Negus SS, Henriksen SJ, Mattox A, Pasternak GW, Portoghese PS, Takemori AE, et al. Effect of antagonists selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats. J Pharmacol Exp Ther. 1993;265(3):1245\u201352.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1300_CR54","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s002130050185","volume":"129","author":"G Zernig","year":"1997","unstructured":"Zernig G, Lewis JW, Woods JH. Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception. Psychopharmacology. 1997;129(3):233\u201342. https:\/\/doi.org\/10.1007\/s002130050185.","journal-title":"Psychopharmacology"},{"issue":"3","key":"1300_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1124\/jpet.122.001267","volume":"384","author":"LR Gerak","year":"2023","unstructured":"Gerak LR, France CP. Attenuation of the positive-reinforcing effects of ultra-potent fentanyl analogs, along with those of fentanyl and heroin, during daily treatment with methocinnamox in Rhesus monkeys. J Pharmacol Exp Ther. 2023;384(3):363\u201371. https:\/\/doi.org\/10.1124\/jpet.122.001267.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1300_CR56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00213-006-0509-x","volume":"189","author":"MA Sullivan","year":"2006","unstructured":"Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology. 2006;189(1):37\u201346. https:\/\/doi.org\/10.1007\/s00213-006-0509-x.","journal-title":"Psychopharmacology"},{"issue":"7","key":"1300_CR57","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/add.14180","volume":"113","author":"BP Jarvis","year":"2018","unstructured":"Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113(7):1188\u2013209. https:\/\/doi.org\/10.1111\/add.14180.","journal-title":"Addiction"},{"key":"1300_CR58","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/add.14735","volume":"115","author":"EV Nunes","year":"2019","unstructured":"Nunes EV, Bisaga A, Krupitsky E, Nangia N, Silverman BL, Akerman SC, et al. Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. Addiction. 2019;115:239\u201346. https:\/\/doi.org\/10.1111\/add.14735.","journal-title":"Addiction"},{"issue":"2","key":"1300_CR59","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0022-3565(25)33600-1","volume":"225","author":"N Mello","year":"1983","unstructured":"Mello N, Bree M, Mendelson J. Comparison of buprenorphine and methadone effects on opiate self-administration in primates. J Pharmacol Exp Ther. 1983;225(2):378\u201386.","journal-title":"J Pharmacol Exp Ther"},{"key":"1300_CR60","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","volume":"74","author":"SL Walsh","year":"2017","unstructured":"Walsh SL, Comer SD, Lofwall MR, Vince B, Levy-Cooperman N, Kelsh D, et al. Effect of buprenorphine weekly depot (CAM2038) and hydromorphine blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psychiat. 2017;74:894\u2013902. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1874.","journal-title":"JAMA Psychiat"},{"issue":"4","key":"1300_CR61","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s00213-001-0975-0","volume":"160","author":"MK Greenwald","year":"2002","unstructured":"Greenwald MK, Schuh KJ, Hopper JA, Schuster CR, Johanson C-E. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology. 2002;160(4):344\u201352. https:\/\/doi.org\/10.1007\/s00213-001-0975-0.","journal-title":"Psychopharmacology"},{"issue":"4","key":"1300_CR62","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s00213-005-0023-6","volume":"181","author":"SD Comer","year":"2005","unstructured":"Comer SD, Walker EA, Collins ED. Buprenorphine\/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology. 2005;181(4):664\u201375. https:\/\/doi.org\/10.1007\/s00213-005-0023-6.","journal-title":"Psychopharmacology"},{"key":"1300_CR63","unstructured":"Food and Drug Administration. The voice of the patient: opioid use disorder. Center for Drug Evaluation and Research: US Food and Drug Administration; 2018. https:\/\/www.fda.gov\/media\/124391\/download."},{"issue":"3","key":"1300_CR64","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1124\/jpet.108.139196","volume":"326","author":"ZD Cooper","year":"2008","unstructured":"Cooper ZD, Truong YN-T, Shi Y-G, Woods JH. Morphine deprivation increases self-administration of the fast- and short-acting \u03bc-opioid receptor agonist remifentanil in the rat. J Pharmacol Exp Ther. 2008;326(3):920\u20139. https:\/\/doi.org\/10.1124\/jpet.108.139196.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"1300_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025799","volume":"9","author":"J Klimas","year":"2019","unstructured":"Klimas J, Gorfinkel L, Giacomuzzi SM, Ruckes C, Socias ME, Fairbairn N, et al. Slow release oral morphine versus methadone for the treatment of opioid use disorder. BMJ Open. 2019;9(4):e025799. https:\/\/doi.org\/10.1136\/bmjopen-2018-025799.","journal-title":"BMJ Open"},{"issue":"2","key":"1300_CR66","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/10550881003684798","volume":"29","author":"MJ Kreek","year":"2010","unstructured":"Kreek MJ, Borg L, Ducat E, Ray B. Pharmacotherapy in the treatment of addiction: methadone. J Addict Dis. 2010;29(2):200\u201316. https:\/\/doi.org\/10.1080\/10550881003684798.","journal-title":"J Addict Dis"},{"issue":"2","key":"1300_CR67","doi-asserted-by":"publisher","first-page":"CD002207","DOI":"10.1002\/14651858.CD002207.pub4","volume":"6","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;6(2):CD002207. https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"1300_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00742","volume":"9","author":"F Noble","year":"2018","unstructured":"Noble F, Marie N. Management of opioid addiction with opioid substitution treatments: beyond methadone and buprenorphine. Front Psychiatry. 2018;9:742. https:\/\/doi.org\/10.3389\/fpsyt.2018.00742.","journal-title":"Front Psychiatry"},{"key":"1300_CR69","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S0022-3565(24)39007-X","volume":"295","author":"MA Kling","year":"2000","unstructured":"Kling MA, Carson RE, Zametkin A, Matochik JA, Schluger J, Herscovitch P, et al. Opioid receptor imaging with positron emission tomography and [18F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther. 2000;295:1070\u20136. https:\/\/doi.org\/10.1016\/S0022-3565(24)39007-X.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1300_CR70","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1124\/jpet.104.072686","volume":"312","author":"JK Melichar","year":"2005","unstructured":"Melichar JK, Hume SP, Williams TM, Daglish MR, Taylor LG, Ahmad R, et al. Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharmacol Exp Ther. 2005;312(1):309\u201315. https:\/\/doi.org\/10.1124\/jpet.104.072686.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"1300_CR71","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/jcbfm.2014.117","volume":"34","author":"DR Quelch","year":"2014","unstructured":"Quelch DR, Katsouri L, Nutt DJ, Parker CA, Tyacke RJ. Imaging endogenous opioid peptide release with [11C]carfentanil and [3H]diprenorphine: influence of agonist-induced internalization. J Cereb Blood Flow Metab. 2014;34(10):1604\u201312. https:\/\/doi.org\/10.1038\/jcbfm.2014.117.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"11","key":"1300_CR72","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","volume":"28","author":"MK Greenwald","year":"2003","unstructured":"Greenwald MK, Johanson C-E, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, et al. Effects of buprenorphine maintenance dose on \u03bc-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28(11):2000\u20139. https:\/\/doi.org\/10.1038\/sj.npp.1300251.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"1300_CR73","first-page":"1207","volume":"29","author":"MC Lee","year":"1988","unstructured":"Lee MC, Wagner HN, Tanada S, Frost JJ, Bice AN, Dannals RF. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med. 1988;29(7):1207\u201311.","journal-title":"J Nucl Med"},{"issue":"3","key":"1300_CR74","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/sj.npp.1301440","volume":"33","author":"EM Weerts","year":"2008","unstructured":"Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ, et al. Differences in \u03b4- and \u03bc-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008;33(3):653\u201365. https:\/\/doi.org\/10.1038\/sj.npp.1301440.","journal-title":"Neuropsychopharmacology"},{"key":"1300_CR75","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134708","author":"ND Volkow","year":"2019","unstructured":"Volkow ND, Blanco C. Medications for opioid use disorders: clinical and pharmacological considerations. J Clin Invest. 2019. https:\/\/doi.org\/10.1172\/JCI134708.","journal-title":"J Clin Invest"},{"issue":"9291","key":"1300_CR76","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-673(01)06529-1","volume":"358","author":"J Rehm","year":"2001","unstructured":"Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet. 2001;358(9291):1417\u201320. https:\/\/doi.org\/10.1016\/S0140-673(01)06529-1.","journal-title":"Lancet"},{"issue":"3","key":"1300_CR77","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1901\/jeab.1981.35-335","volume":"35","author":"RR Griffiths","year":"1981","unstructured":"Griffiths RR, Wurster RM, Brady JV. Choice between food and heroin: effects of morphine, naloxone, and secobarbital. J Exp Anal Behav. 1981;35(3):335\u201351.","journal-title":"J Exp Anal Behav"},{"issue":"4","key":"1300_CR78","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/npp.2008.127","volume":"34","author":"SS Negus","year":"2009","unstructured":"Negus SS, Rice KC. Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs food choice in heroin-dependent Rhesus monkeys. Neuropsychopharmacology. 2009;34(4):899\u2013911. https:\/\/doi.org\/10.1038\/npp.2008.127.","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"1300_CR79","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1111\/add.12315","volume":"108","author":"RN Rosenthal","year":"2013","unstructured":"Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine\/naloxone. Addiction. 2013;108(12):2141\u20139.","journal-title":"Addiction"},{"issue":"10173","key":"1300_CR80","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","volume":"393","author":"BR Haight","year":"2019","unstructured":"Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;393(10173):778\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(18)32259-1.","journal-title":"Lancet"},{"issue":"12","key":"1300_CR81","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","volume":"74","author":"L Tanum","year":"2017","unstructured":"Tanum L, Solli K, Latif Z, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiat. 2017;74(12):1197\u2013205. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.3206.","journal-title":"JAMA Psychiat"},{"issue":"10118","key":"1300_CR82","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","volume":"391","author":"JD Lee","year":"2018","unstructured":"Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(17)32812-X.","journal-title":"Lancet"},{"issue":"11","key":"1300_CR83","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1021\/acsptsci.2c00178","volume":"5","author":"PP Pagare","year":"2022","unstructured":"Pagare PP, Obeng S, Huang B, Marcus MM, Nicholson KL, Townsend AE, et al. Preclinical characterization and development on NAQ as a Mu opioid receptor partial agonist for opioid use disorder treatment. ACS Pharmacol Transl Sci. 2022;5(11):1197\u2013209. https:\/\/doi.org\/10.1021\/acsptsci.2c00178.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"4","key":"1300_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1111","volume":"11","author":"EJ Santos","year":"2023","unstructured":"Santos EJ, Nassehi N, Bow EW, Chambers DR, Gutman Eugene S, Jacobson AE, et al. Role of efficacy as a determinant of locomotor activation by mu-opioid receptor (MOR) ligands in female and male mice. II. Effects of novel MOR-selective phenylmorphans with high-to-low MOR efficacy. Pharmacol Res Perspect. 2023;11(4):e01111. https:\/\/doi.org\/10.1002\/prp2.1111.","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"1300_CR85","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1124\/jpet.124.002153","volume":"391","author":"EJ Santos","year":"2024","unstructured":"Santos EJ, Akbarali HI, Bow EW, Chambers DR, Gutman ES, Jacobson AE, et al. Low-efficacy Mu opioid agonists as candidate analgesics: effects of novel C-9 substituted phenylmorphans on pain-depressed behavior in mice. J Pharmacol Exp Ther. 2024;391(2):138\u201351. https:\/\/doi.org\/10.1124\/jpet.124.002153.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"1300_CR86","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1021\/acschemneuro.5c00211","volume":"16","author":"DE Hernandez","year":"2025","unstructured":"Hernandez DE, Luo D, Prisinzano TE, Negus SS, Nassehi N, Selley DE, et al. Transformation of a potent C9-substituted phenylmorphan into MOR partial agonists with improvement of metabolic stability: an in vitro, in vivo, and in silico study. ACS Chem Neurosci. 2025;16(11):2110\u201327. https:\/\/doi.org\/10.1021\/acschemneuro.5c00211.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"1300_CR87","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12954-023-00731-y","volume":"20","author":"M Vogel","year":"2023","unstructured":"Vogel M, Meyer M, Westenberg JN, Kormann A, Simon O, Salim Hassan Fadlelseed R, et al. Safety and feasibility of intranasal heroin-assisted treatment: 4-week preliminary findings from a Swiss multicentre observational study. Harm Reduct J. 2023;20(1):2. https:\/\/doi.org\/10.1186\/s12954-023-00731-y.","journal-title":"Harm Reduct J"},{"issue":"8","key":"1300_CR88","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40263-025-01189-1","volume":"39","author":"A Guessoum","year":"2025","unstructured":"Guessoum A, Vogt SB, Meyer M, Westenberg JN, Klemperer B, D\u00fcrsteler KM, et al. Pharmacokinetics and pharmacodynamics of intranasal diacetylmorphine in heroin-assisted treatment for severe opioid use disorder. CNS Drugs. 2025;39(8):807\u201317. https:\/\/doi.org\/10.1007\/s40263-025-01189-1.","journal-title":"CNS Drugs"},{"key":"1300_CR89","doi-asserted-by":"publisher","unstructured":"Nader MA. Chapter 1\u2014Animal models for addiction medicine: from vulnerable phenotypes to addicted individuals. In: Hamed E, Martin PP, editors. Prog. brain res. Elsevier; 2016. p. 3\u201324. https:\/\/doi.org\/10.1016\/bs.pbr.2015.07.012.","DOI":"10.1016\/bs.pbr.2015.07.012"},{"issue":"1","key":"1300_CR90","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1124\/jpet.118.252353","volume":"368","author":"DR Maguire","year":"2019","unstructured":"Maguire DR, Gerak LR, Woods JH, Husbands SM, Disney A, France CP. Long-lasting effects of methocinnamox on opioid self-administration in Rhesus monkeys. J Pharmacol Exp Ther. 2019;368(1):88\u201399. https:\/\/doi.org\/10.1124\/jpet.118.252353.","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"1300_CR91","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/s41386-020-0698-8","volume":"45","author":"DR Maguire","year":"2020","unstructured":"Maguire DR, Gerak LR, Sanchez JJ, Javors MA, Disney A, Husbands SM, et al. Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in Rhesus monkeys. Neuropsychopharmacology. 2020;45(12):1986\u201393. https:\/\/doi.org\/10.1038\/s41386-020-0698-8.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"1300_CR92","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1124\/jpet.122.001233","volume":"382","author":"DR Maguire","year":"2022","unstructured":"Maguire DR, France CP. Effects of daily methocinnamox treatment on fentanyl self-administration in Rhesus monkeys. J Pharmacol Exp Ther. 2022;382(2):181\u20137. https:\/\/doi.org\/10.1124\/jpet.122.001233.","journal-title":"J Pharmacol Exp Ther"},{"key":"1300_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109777","volume":"243","author":"DR Maguire","year":"2024","unstructured":"Maguire DR, France CP. Daily methocinnamox treatment dose-dependently attenuates fentanyl self-administration in Rhesus monkeys. Neuropharmacology. 2024;243:109777. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109777.","journal-title":"Neuropharmacology"},{"issue":"5","key":"1300_CR94","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.tcm.2023.03.006","volume":"34","author":"A El Sherbini","year":"2024","unstructured":"El Sherbini A, Liblik K, Lee J, Baranchuk A, Zhang S, El-Diasty M. Opioids-induced inhibition of HERG ion channels and sudden cardiac death, a systematic review of current literature. Trends Cardiovasc Med. 2024;34(5):279\u201385. https:\/\/doi.org\/10.1016\/j.tcm.2023.03.006.","journal-title":"Trends Cardiovasc Med"},{"key":"1300_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.123041","volume":"317","author":"H Sudarjat","year":"2025","unstructured":"Sudarjat H, Qin C, Ingabire D, Moothedathu Raynold AA, Pangeni R, Pearcy A, et al. Janus LAAM-loaded electrospun fibrous buccal films for treating opioid use disorder. Biomaterials. 2025;317:123041. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.123041.","journal-title":"Biomaterials"},{"key":"1300_CR96","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jconrel.2024.06.071","volume":"373","author":"D Ingabire","year":"2024","unstructured":"Ingabire D, Qin C, Meng T, Raynold AAM, Sudarjat H, Townsend EA, et al. Nor-LAAM loaded PLGA microparticles for treating opioid use disorder. J Control Release. 2024;373:93\u2013104. https:\/\/doi.org\/10.1016\/j.jconrel.2024.06.071.","journal-title":"J Control Release"},{"key":"1300_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2026.114722","volume":"392","author":"A Otte","year":"2026","unstructured":"Otte A, Park K. Compacted solid implant formulations for long-term buprenorphine delivery. J Control Release. 2026;392:114722. https:\/\/doi.org\/10.1016\/j.jconrel.2026.114722.","journal-title":"J Control Release"},{"issue":"5","key":"1300_CR98","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nrn3939","volume":"16","author":"DJ Nutt","year":"2015","unstructured":"Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PRA. The dopamine theory of addiction: 40 years of highs and lows. Nat Rev Neurosci. 2015;16(5):305\u201312.","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"1300_CR99","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nrn3939","volume":"16","author":"RA Wise","year":"2015","unstructured":"Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci. 2015;16(5):305\u201312. https:\/\/doi.org\/10.1038\/nrn3939.","journal-title":"Nat Rev Neurosci"},{"issue":"14","key":"1300_CR100","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","volume":"85","author":"G Di Chiara","year":"1988","unstructured":"Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA. 1988;85(14):5274\u20138. https:\/\/doi.org\/10.1073\/pnas.85.14.5274.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1300_CR101","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1523\/JNEUROSCI.12-02-00483.1992","volume":"12","author":"SW Johnson","year":"1992","unstructured":"Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 1992;12(2):483\u20138. https:\/\/doi.org\/10.1523\/JNEUROSCI.12-02-00483.1992.","journal-title":"J Neurosci"},{"key":"1300_CR102","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.39945","volume":"7","author":"J Corre","year":"2018","unstructured":"Corre J, van Zessen R, Loureiro M, Patriarchi T, Tian L, Pascoli V, et al. Dopamine neurons projecting to medial shell of the nucleus accumbens drive heroin reinforcement. Elife. 2018;7:e39945. https:\/\/doi.org\/10.7554\/eLife.39945.","journal-title":"Elife"},{"key":"1300_CR103","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.tips.2016.11.002","volume":"38","author":"ML Banks","year":"2017","unstructured":"Banks ML, Negus SS. Insights from preclinical choice models on treating drug addiction. Trends Pharmacol Sci. 2017;38:181\u201394. https:\/\/doi.org\/10.1016\/j.tips.2016.11.002.","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"1300_CR104","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr5051","volume":"11","author":"R Merkel","year":"2025","unstructured":"Merkel R, Hernandez NS, Weir V, Zhang Y, Caffrey A, Rich MT, et al. An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Sci Adv. 2025;11(9):eadr5051. https:\/\/doi.org\/10.1126\/sciadv.adr5051.","journal-title":"Sci Adv"},{"key":"1300_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107312","volume":"207","author":"VN Bruns","year":"2024","unstructured":"Bruns VN, Tressler EH, Vendruscolo LF, Leggio L, Farokhnia M. IUPHAR review\u2014glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target. Pharmacol Res. 2024;207:107312. https:\/\/doi.org\/10.1016\/j.phrs.2024.107312.","journal-title":"Pharmacol Res"},{"key":"1300_CR106","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2025.10038","volume":"37","author":"HCT Au","year":"2025","unstructured":"Au HCT, Lam PH, Kabir F, Huang CL, Dri CE, Le GH, et al. Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review. Acta Neuropsychiatr. 2025;37:e85. https:\/\/doi.org\/10.1017\/neu.2025.10038.","journal-title":"Acta Neuropsychiatr"},{"issue":"2","key":"1300_CR107","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0000000000000685","volume":"27","author":"JE Douton","year":"2022","unstructured":"Douton JE, Horvath N, Mills-Huffnagle S, Nyland JE, Hajnal A, Grigson PS. Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats. Addict Biol. 2022;27(2):e13117. https:\/\/doi.org\/10.1097\/FBP.0000000000000685.","journal-title":"Addict Biol"},{"key":"1300_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108599","volume":"192","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Rahematpura S, Ragnini KH, Moreno A, Stecyk KS, Kahng MW, et al. A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats. Neuropharmacology. 2021;192:108599. https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108599.","journal-title":"Neuropharmacology"},{"issue":"18","key":"1300_CR109","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1111\/bph.70096","volume":"182","author":"A Caffrey","year":"2025","unstructured":"Caffrey A, Lavecchia E, Chichura KS, Hayes MR, Doyle RP, Schmidt HD. A GLP-1R\/Y1 receptor\/Y2 receptor triple agonist decreases fentanyl-evoked dopamine release in the nucleus accumbens and attenuates fentanyl taking and seeking in rats. Br J Pharmacol. 2025;182(18):4363\u201379. https:\/\/doi.org\/10.1111\/bph.70096.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1300_CR110","doi-asserted-by":"publisher","DOI":"10.1523\/eneuro.0443-18.2019","volume":"6","author":"AB Bornebusch","year":"2019","unstructured":"Bornebusch AB, Fink-Jensen A, W\u00f6rtwein G, Seeley RJ, Thomsen M. Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs. eNeuro. 2019;6(2):ENEURO.0443\u201318.2019. https:\/\/doi.org\/10.1523\/eneuro.0443-18.2019.","journal-title":"eNeuro"},{"issue":"15","key":"1300_CR111","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","volume":"187","author":"CM Kusminski","year":"2024","unstructured":"Kusminski CM, Perez-Tilve D, M\u00fcller TD, DiMarchi RD, Tsch\u00f6p MH, Scherer PE. Transforming obesity: the advancement of multi-receptor drugs. Cell. 2024;187(15):3829\u201353. https:\/\/doi.org\/10.1016\/j.cell.2024.06.003.","journal-title":"Cell"},{"key":"1300_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pnpbp.2013.12.018","volume":"51","author":"S-C Kuo","year":"2014","unstructured":"Kuo S-C, Yeh Y-W, Chen C-Y, Huang C-C, Chang H-A, Yen C-H, et al. DRD3 variation associates with early-onset heroin dependence, but not specific personality traits. Prog Neuropsychopharmacol Biol Psychiatry. 2014;51:1\u20138. https:\/\/doi.org\/10.1016\/j.pnpbp.2013.12.018.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"1300_CR113","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41397-021-00212-0","volume":"21","author":"D Bright","year":"2021","unstructured":"Bright D, Langerveld A, DeVuyst-Miller S, Saadeh C, Choker A, Lehigh E, et al. Identification of a sex-stratified genetic algorithm for opioid addiction risk. Pharmacogenomics J. 2021;21(3):326\u201335. https:\/\/doi.org\/10.1038\/s41397-021-00212-0.","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"1300_CR114","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/cpt.2864","volume":"113","author":"CE Freiermuth","year":"2023","unstructured":"Freiermuth CE, Kisor DF, Lambert J, Braun R, Frey JA, Bachmann DJ, et al. Genetic variants associated with opioid use disorder. Clin Pharmacol Ther. 2023;113(5):1089\u201395. https:\/\/doi.org\/10.1002\/cpt.2864.","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"1300_CR115","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.2217\/pgs.14.145","volume":"15","author":"O Levran","year":"2014","unstructured":"Levran O, Peles E, Randesi M, Correa da Rosa J, Ott J, Rotrosen J, et al. Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variants. Pharmacogenomics. 2014;15(16):2001\u20139. https:\/\/doi.org\/10.2217\/pgs.14.145.","journal-title":"Pharmacogenomics"},{"key":"1300_CR116","doi-asserted-by":"publisher","unstructured":"Newman AH, Xi Z-X, Heidbreder C. Current perspectives on selective dopamine D3 receptor antagonists\/partial agonists as pharmacotherapeutics for opioid and psychostimulant use disorders. In: Boileau I, Collo G, editors. Therapeutic applications of dopamine D3 receptor function: new insight after 30 years of research. Cham: Springer International Publishing; 2023. p. 157\u2013201. https:\/\/doi.org\/10.1007\/7854_2022_347.","DOI":"10.1007\/7854_2022_347"},{"key":"1300_CR117","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.neuropharm.2017.09.007","volume":"126","author":"Z-B You","year":"2017","unstructured":"You Z-B, Gao J-T, Bi G-H, He Y, Boateng C, Cao J, et al. The novel dopamine D3 receptor antagonists\/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats. Neuropharmacology. 2017;126:190\u20139. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.007.","journal-title":"Neuropharmacology"},{"issue":"13","key":"1300_CR118","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/s41386-022-01379-1","volume":"47","author":"E Galaj","year":"2022","unstructured":"Galaj E, Bi G-H, Klein B, Hempel B, Shaik AB, Gogarnoiu ES, et al. A highly D3R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D3R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder. Neuropsychopharmacology. 2022;47(13):2309\u201318. https:\/\/doi.org\/10.1038\/s41386-022-01379-1.","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"1300_CR119","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/s41386-023-01590-8","volume":"48","author":"K Woodlief","year":"2023","unstructured":"Woodlief K, Allen MI, Cornelissen JC, Banks ML, Newman AH, Nader MA. Effects of selective dopamine D3 receptor partial agonist\/antagonists on oxycodone self-administration and antinociception in monkeys. Neuropsychopharmacology. 2023;48(12):1716\u201323. https:\/\/doi.org\/10.1038\/s41386-023-01590-8.","journal-title":"Neuropsychopharmacology"},{"key":"1300_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.addicn.2023.100065","author":"AS Amirali","year":"2023","unstructured":"Amirali AS, Hecker JC, Figueroa HM, Effinger DP, Montoro RA, Jedema HP, et al. Effects of buprenorphine, methadone, and cariprazine on economic choice between remifentanil and food in squirrel monkeys. Addict Neurosci. 2023. https:\/\/doi.org\/10.1016\/j.addicn.2023.100065.","journal-title":"Addict Neurosci."},{"key":"1300_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2019.00292","author":"G de Guglielmo","year":"2020","unstructured":"de Guglielmo G, Kallupi M, Sedighim S, Newman AH, George O. Dopamine D3 receptor antagonism reverses the escalation of oxycodone self-administration and decreases withdrawal-induced hyperalgesia and irritability-like behavior in oxycodone-dependent heterogeneous stock rats. Front Behavl Neurosci. 2020. https:\/\/doi.org\/10.3389\/fnbeh.2019.00292.","journal-title":"Front Behavl Neurosci."},{"issue":"2","key":"1300_CR122","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0006-8993(98)00529-0","volume":"800","author":"B Levant","year":"1998","unstructured":"Levant B. Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res. 1998;800(2):269\u201374.","journal-title":"Brain Res"},{"issue":"8","key":"1300_CR123","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/j.1360-0443.2005.01154.x","volume":"100","author":"W Ling","year":"2005","unstructured":"Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, et al. A multi-center randomized trial of buprenorphine\u2013naloxone versus clonidine for opioid, detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005;100(8):1090\u2013100. https:\/\/doi.org\/10.1111\/j.1360-0443.2005.01154.x.","journal-title":"Addiction"},{"issue":"8","key":"1300_CR124","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1176\/appi.ajp.2014.14081014","volume":"172","author":"WJ Kowalczyk","year":"2015","unstructured":"Kowalczyk WJ, Phillips KA, Jobes ML, Kennedy AP, Ghitza UE, Agage DA, et al. Clonidine maintenance prolongs opioid abstinence and decouples stress from craving in daily life: a randomized controlled trial with ecological momentary assessment. Am J Psychiatry. 2015;172(8):760\u20137. https:\/\/doi.org\/10.1176\/appi.ajp.2014.14081014.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1300_CR125","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1124\/pr.114.009209","volume":"68","author":"L Toll","year":"2016","unstructured":"Toll L, Bruchas MR, Calo\u2019 G, Cox BM, Zaveri NT. Nociceptin\/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev. 2016;68(2):419\u201357. https:\/\/doi.org\/10.1124\/pr.114.009209.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"1300_CR126","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1124\/jpet.114.213694","volume":"349","author":"K Linz","year":"2014","unstructured":"Linz K, Christoph T, Tzschentke TM, Koch T, Schiene K, Gautrois M, et al. Cebranopadol: a novel potent analgesic nociceptin\/orphanin FQ peptide and opioid receptor agonist. J Pharmacol Exp Ther. 2014;349(3):535\u201348. https:\/\/doi.org\/10.1124\/jpet.114.213694.","journal-title":"J Pharmacol Exp Ther"},{"issue":"37","key":"1300_CR127","doi-asserted-by":"publisher","first-page":"E5511","DOI":"10.1073\/pnas.1605295113","volume":"113","author":"H Ding","year":"2016","unstructured":"Ding H, Czoty PW, Kiguchi N, Cami-Kobeci G, Sukhtankar DD, Nader MA, et al. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proc Natl Acad Sci USA. 2016;113(37):E5511\u20138. https:\/\/doi.org\/10.1073\/pnas.1605295113.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"456","key":"1300_CR128","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar3483","volume":"10","author":"H Ding","year":"2018","unstructured":"Ding H, Kiguchi N, Yasuda D, Daga PR, Polgar WE, Lu JJ, et al. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. Sci Trans Med. 2018;10(456):eaar3483. https:\/\/doi.org\/10.1126\/scitranslmed.aar3483.","journal-title":"Sci Trans Med"},{"issue":"3","key":"1300_CR129","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jpainsymman.2019.05.012","volume":"58","author":"ED Koch","year":"2019","unstructured":"Koch ED, Kapanadze S, Eerdekens M-H, Kralidis G, L\u00e9tal J, Sabatschus I, et al. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience with cancer-related pain for up to 26 weeks. J Pain Symptom Manag. 2019;58(3):390\u20139. https:\/\/doi.org\/10.1016\/j.jpainsymman.2019.05.012.","journal-title":"J Pain Symptom Manag"},{"issue":"3","key":"1300_CR130","doi-asserted-by":"publisher","first-page":"E193","DOI":"10.36076\/ppj.2018.3.E193","volume":"21","author":"A Scholz","year":"2018","unstructured":"Scholz A, Bothmer J, Kok M, Hoschen K, Daniels S. Cebranopadol: a novel, first-in-class, strong analgesic: results from a randomized phase IIa clinical trial in postoperative acute pain. Pain Physician. 2018;21(3):E193\u2013206.","journal-title":"Pain Physician"},{"issue":"1","key":"1300_CR131","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JCP.0000000000000995","volume":"39","author":"K Gohler","year":"2019","unstructured":"Gohler K, Sokolowska M, Schoedel KA, Nemeth R, Kleideiter E, Szeto I, et al. Assessment of the abuse potential of cebranopadol in nondependent recreational opioid users: a phase 1 randomized controlled study. J Clin Psychopharmacol. 2019;39(1):46\u201356. https:\/\/doi.org\/10.1097\/JCP.0000000000000995.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"1300_CR132","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bph.15679","volume":"179","author":"JM Bossert","year":"2022","unstructured":"Bossert JM, Townsend EA, Altidor LK-P, Fredriksson I, Shekara A, Husbands S, et al. Sex differences in the effect of chronic delivery of the buprenorphine analogue BU08028 on heroin relapse and choice in a rat model of opioid maintenance. Br J Pharmacol. 2022;179(2):227\u201341. https:\/\/doi.org\/10.1111\/bph.15679.","journal-title":"Br J Pharmacol"},{"issue":"12","key":"1300_CR133","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1007\/s00213-024-06678-7","volume":"241","author":"JM Bossert","year":"2024","unstructured":"Bossert JM, Caldwell KE, Korah H, Batista A, Bonbrest H, Fredriksson I, et al. Effect of chronic delivery of the NOP\/MOR partial agonist AT-201 and NOP antagonist J-113397 on heroin relapse in a rat model of opioid maintenance. Psychopharmacology. 2024;241(12):2497\u2013511. https:\/\/doi.org\/10.1007\/s00213-024-06678-7.","journal-title":"Psychopharmacology"},{"issue":"3","key":"1300_CR134","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0740-5472(03)00191-0","volume":"26","author":"MD Stein","year":"2004","unstructured":"Stein MD, Herman DS, Bishop S, Lassor JA, Weinstock M, Anthony J, et al. Sleep disturbances among methadone maintained patients. J Subst Abuse Treat. 2004;26(3):175\u201380. https:\/\/doi.org\/10.1016\/S0740-5472(03)00191-0.","journal-title":"J Subst Abuse Treat"},{"key":"1300_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2022.107433","volume":"135","author":"LF Berro","year":"2022","unstructured":"Berro LF, Zamarripa CA, Talley JT, Freeman KB, Rowlett JK. Effects of methadone, buprenorphine, and naltrexone on actigraphy-based sleep-like parameters in male rhesus monkeys. Addict Behav. 2022;135:107433. https:\/\/doi.org\/10.1016\/j.addbeh.2022.107433.","journal-title":"Addict Behav"},{"issue":"4","key":"1300_CR136","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1124\/mol.119.119107","volume":"98","author":"D Eacret","year":"2020","unstructured":"Eacret D, Veasey SC, Blendy JA. Bidirectional relationship between opioids and disrupted sleep: putative mechanisms. Mol Pharmacol. 2020;98(4):445\u201353. https:\/\/doi.org\/10.1124\/mol.119.119107.","journal-title":"Mol Pharmacol"},{"issue":"650","key":"1300_CR137","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn8238","volume":"14","author":"AS Huhn","year":"2022","unstructured":"Huhn AS, Finan PH, Gamaldo CE, Hammond AS, Umbricht A, Bergeria CL, et al. Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Sci Trans Med. 2022;14(650):eabn8238. https:\/\/doi.org\/10.1126\/scitranslmed.abn8238.","journal-title":"Sci Trans Med"},{"key":"1300_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1127735","author":"JM Illenberger","year":"2023","unstructured":"Illenberger JM, Flores-Ramirez FJ, Matzeu A, Mason BJ, Martin-Fardon R. Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1127735.","journal-title":"Front Pharmacol"},{"key":"1300_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.112434","volume":"264","author":"EDC Moreira-Junior","year":"2024","unstructured":"Moreira-Junior EDC, Rowlett JK, Berro LF. Suvorexant enhances oxycodone-induced respiratory depression in male rats. Drug Alcohol Depend. 2024;264:112434. https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.112434.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"1300_CR140","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1474-8673.1982.tb00520.x","volume":"2","author":"RR Ruffolo","year":"1982","unstructured":"Ruffolo RR. Important concepts of receptor theory. J Auton Pharmacol. 1982;2(4):277\u201395. https:\/\/doi.org\/10.1111\/j.1474-8673.1982.tb00520.x.","journal-title":"J Auton Pharmacol"},{"key":"1300_CR141","volume-title":"Pharmacologic analysis of drug receptor interaction","author":"T Kenakin","year":"1993","unstructured":"Kenakin T. Pharmacologic analysis of drug receptor interaction. 2nd ed. New York: Raven Press; 1993.","edition":"2"},{"key":"1300_CR142","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/ajad.70030","volume":"34","author":"N Sood","year":"2025","unstructured":"Sood N. Rise of illicit medetomidine use: a worrisome trend. Am J Addict. 2025;34:558\u201361. https:\/\/doi.org\/10.1111\/ajad.70030.","journal-title":"Am J Addict"},{"issue":"15","key":"1300_CR143","doi-asserted-by":"publisher","first-page":"258","DOI":"10.15585\/mmwr.mm7415a1","volume":"74","author":"A Nham","year":"2025","unstructured":"Nham A, Le JN, Thomas SA, Gressick K, Ussery EN, Ko JY, et al. Overdoses involving medetomidine mixed with opioids\u2014Chicago, Illinois, May 2024. MMWR Morb Mortal Wkly Rep. 2025;74(15):258\u201365. https:\/\/doi.org\/10.15585\/mmwr.mm7415a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1300_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2025.112703","volume":"273","author":"E Jackson","year":"2025","unstructured":"Jackson E, Bach P, Socias ME, Brooks OM, Fairbairn N, Rodrigues M, et al. Trends in stimulant use among patients with opioid use disorder receiving substance use treatment: findings from a prospective cohort study from 2013 to 2020. Drug Alcohol Depend. 2025;273:112703. https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112703.","journal-title":"Drug Alcohol Depend"},{"key":"1300_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111282","volume":"258","author":"CM St. Onge","year":"2024","unstructured":"St. Onge CM, Canfield JR, Ortiz A, Sprague JE, Banks ML. Xylazine does not enhance fentanyl reinforcement in rats: a behavioral economic analysis. Drug Alcohol Depend. 2024;258:111282. https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.111282.","journal-title":"Drug Alcohol Depend"},{"key":"1300_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2025.103717","author":"A Ortiz","year":"2025","unstructured":"Ortiz A, St. Onge CM, Banks ML. Fixed-proportion mixtures with the \u03b12-adrenergic agonist clonidine or lofexidine do not alter fentanyl self-administration in non\u2013opioid-dependent male and female rats. J Pharmacol Exp Ther. 2025. https:\/\/doi.org\/10.1016\/j.jpet.2025.103717.","journal-title":"J Pharmacol Exp Ther"},{"key":"1300_CR147","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1037\/pha0000670","volume":"32","author":"SN Khatri","year":"2023","unstructured":"Khatri SN, Sadek S, Kendrick PT, Bondy EO, Hong M, Pauss S, et al. Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats. Exp Clin Psychopharmacol. 2023;32:150\u20137. https:\/\/doi.org\/10.1037\/pha0000670.","journal-title":"Exp Clin Psychopharmacol"},{"key":"1300_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109816","volume":"245","author":"SM Sadek","year":"2024","unstructured":"Sadek SM, Khatri SN, Kipp Z, Dunn KE, Beckmann JS, Stoops WW, et al. Impacts of xylazine on fentanyl demand, body weight, and acute withdrawal in rats: a comparison to lofexidine. Neuropharmacology. 2024;245:109816. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109816.","journal-title":"Neuropharmacology"},{"issue":"3","key":"1300_CR149","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/0091-3057(78)90295-2","volume":"9","author":"A Killian","year":"1978","unstructured":"Killian A, Bonese K, Rothberg RM, Wainer BH, Schuster CR. Effects of passive immunization against morphine on heroin self-administration. Pharmacol Biochem Behav. 1978;9(3):347\u201352. https:\/\/doi.org\/10.1016\/0091-3057(78)90295-2.","journal-title":"Pharmacol Biochem Behav"},{"issue":"16","key":"1300_CR150","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1016\/j.vaccine.2006.01.047","volume":"24","author":"B Anton","year":"2006","unstructured":"Anton B, Leff P. A novel bivalent morphine\/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine. 2006;24(16):3232\u201340. https:\/\/doi.org\/10.1016\/j.vaccine.2006.01.047.","journal-title":"Vaccine"},{"issue":"12","key":"1300_CR151","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115696","volume":"9","author":"MD Raleigh","year":"2014","unstructured":"Raleigh MD, Pentel PR, LeSage MG. Pharmacokinetic correlates of the effects of a heroin vaccine on heroin self-administration in rats. PLoS ONE. 2014;9(12):e115696. https:\/\/doi.org\/10.1371\/journal.pone.0115696.","journal-title":"PLoS ONE"},{"issue":"22","key":"1300_CR152","doi-asserted-by":"publisher","first-page":"9036","DOI":"10.1073\/pnas.1219159110","volume":"110","author":"JE Schlosburg","year":"2013","unstructured":"Schlosburg JE, Vendruscolo LF, Bremer PT, Lockner JW, Wade CL, Nunes AAK, et al. Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci USA. 2013;110(22):9036\u201341. https:\/\/doi.org\/10.1073\/pnas.1219159110.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"1300_CR153","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101807","volume":"9","author":"M Pravetoni","year":"2014","unstructured":"Pravetoni M, Pentel PR, Potter DN, Chartoff EH, Tally L, LeSage MG. Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats. PLoS ONE. 2014;9(7):e101807. https:\/\/doi.org\/10.1371\/journal.pone.0101807.","journal-title":"PLoS ONE"},{"issue":"3","key":"1300_CR154","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","volume":"45","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Kahng MW, Elkind JA, Weir VR, Hernandez NS, Stein LM, et al. Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats. Neuropsychopharmacology. 2020;45(3):451\u201361. https:\/\/doi.org\/10.1038\/s41386-019-0531-4.","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"1300_CR155","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41386-018-0284-5","volume":"44","author":"Z-B You","year":"2019","unstructured":"You Z-B, Bi G-H, Galaj E, Kumar V, Cao J, Gadiano A, et al. Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects. Neuropsychopharmacology. 2019;44(8):1415\u201324. https:\/\/doi.org\/10.1038\/s41386-018-0284-5.","journal-title":"Neuropsychopharmacology"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01300-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01300-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01300-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:47:17Z","timestamp":1782380837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01300-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":155,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1300"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01300-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares there are no competing financial interests or potential conflicts of interest in relation to the research described.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No primary data were collected for this manuscript. All data presented in this manuscript are published and referenced.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MLB: conceptualization, visualization, investigation, funding acquisition, writing \u2013 original draft preparation, writing \u2013 review and editing. The author has read and approved the final manuscript version and agrees to be accountable for the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}